InvestorsHub Logo
Followers 8
Posts 481
Boards Moderated 0
Alias Born 02/03/2021

Re: TheBigTicket post# 171940

Friday, 06/25/2021 7:48:28 AM

Friday, June 25, 2021 7:48:28 AM

Post# of 232968
Their trial with partner Regeneron

https://investor.regeneron.com/news-releases/news-release-details/regen-covtm-casirivimab-and-imdevimab-phase-3-recovery-trial

The drug works on virus unlike LL which works on ccr5. 5500 patients. 20% mortality benefit on severe+critical, they claim improvement in ventilation patients as well but have not given the mortality info specific for that subgroup (whether that by itself is stat sig). I don’t follow the seronegative etc. Doctors here can explain if there is other important info from this study relevant to us.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News